Objectives To develop and validate an international set of classification criteria for primary Sjögren's syndrome (SS) using guidelines from the American College of Rheumatology (ACR) and the European ...
Objectives To develop evidence-based recommendations for management of calcium pyrophosphate deposition (CPPD). Methods A multidisciplinary guideline development group of 15 experts, representing 10 ...
1 University of Toronto, Toronto Western Research Institute, Psoriatic Arthritis Program, University Health Network, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, ...
Background Intra-articular injection is effective for osteoarthritis, but the best single injection strategy is not known, nor are there established predictors of response. The objectives of this ...
Background In 2001, the European League Against Rheumatism developed and disseminated the first guidelines for musculoskeletal (MS) ultrasound (US) in rheumatology. Fifteen years later, the dramatic ...
Objectives Osteoarthritis (OA) is the most common degenerative joint disease in aged population and its development is significantly influenced by aberrant epigenetic modifications of numerous OA ...
Background: RTX-GRT7039 (resiniferatoxin; RTX), is a potent and selective agonist of the transient receptor potential vanilloid 1 (TRPV1) being developed for treatment of pain related to knee ...
Objectives The aims of this study were to define the pattern of muscle involvement in patients with immune-mediated necrotising myopathy (IMNM) relative to those with other inflammatory myopathies and ...
Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy Dr M Cutolo, Research Laboratory and Academic Unit of Clinical ...
MRC Environmental Epidemiology Unit, Community Clinical Sciences, University of Southampton, UK Correspondence to: Dr K T Palmer, MRC Environmental Epidemiology Unit, Southampton General Hospital, ...
Background The SELENA flare index (SFI) has functioned well in clinical and clinical trial settings (1), but has the limitation that it classifies only severe versus combined mild/moderate flares.
F8: Back to the future: how to mix the old and new treatments for SLE, Sjögren's and APS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results